SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is actively trending as market participants analyze former President Trump's speech at the World Economic Forum in Davos. His remarks, particularly those concerning Greenland and the broader economic outlook, are sparking intense debate within the community. Discussion centers on whether his bullish pronouncements or controversial international rhetoric will ultimately dictate market sentiment amid geopolitical tensions.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending as Donald Trump's remarks at the World Economic Forum captivate audiences, with community attention centered on his controversial proposals for tariffs and persistent calls to acquire Greenland. These statements are fueling polarized debates regarding their potential impact on international relations and market stability, alongside widespread commentary on his public speaking style.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending after an earnings report that, despite exceeding estimates, has sparked significant debate regarding subscriber growth, cautious guidance, and the strategic implications of its potential Warner Bros. Discovery acquisition. While many view the current dip as an oversold buying opportunity for a market leader, concerns around debt, a paused buyback program, and slower growth are driving a bearish outlook, with the community sharply divided on the stock's immediate future.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is trending following news that its subsidiary, Lucid Diagnostics, was awarded a contract by the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. This development has ignited widespread community discussion, with many highlighting the stock's low share float and speculating about a potential short squeeze, drawing parallels to other recent volatile small-cap movements. Community members are actively debating the contract's impact on PAVmed's valuation, especially given its significant ownership stake in Lucid.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to widespread market discussion around geopolitical tensions, specifically former President Trump's rhetoric on Greenland and trade policy during his Davos address. The community is actively debating whether perceived softening in his stance will alleviate pressure or if broader concerns over trade relations and central bank policy will continue to influence growth-oriented tech assets.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending amid an intense geopolitical spotlight on Greenland's strategic rare earth minerals, fueled by recent statements from a former President emphasizing the territory's importance for national security. The community is actively discussing significant price volatility and potential market manipulation, with many anticipating a major business update from the company as a key catalyst. This narrative positions CRML as a central player in securing a Western critical minerals supply chain, driving strong bullish sentiment among investors despite recent fluctuations.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing heightened investor attention and bullish momentum as multiple analyst upgrades and anticipation of its upcoming earnings report fuel a narrative of a strong turnaround. The community is actively discussing its resilience and upward trajectory, particularly given its performance on down market days, with many highlighting its strategic position in AI and domestic manufacturing capabilities amidst robust demand.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is seeing intense discussion driven by former President Trump's remarks from Davos, emphasizing his supportive stance towards the crypto industry and potential legislative action. This has polarized the community, with many anticipating a major rally and a "super cycle" in digital assets, while a segment expresses caution, labeling recent price action as a "bear trap" amid ongoing market volatility.

Aqua Metals, Inc. engages in reinventing metal recycling technologies. Its patented technology, AquaRefining, replaces polluting furnaces and hazardous chemicals with electricity-powered electroplating to recover valuable metals and materials from spent batteries with higher purity, lower emissions, and minimal waste. The company was founded by Stephen R. Clarke, Thomas Murphy, and Selwyn Mould on June 20, 2014 and is headquartered in Reno, NV.

Aqua Metals Inc

Aqua Metals is trending after announcing a multi-year supply agreement with 6K Energy, reinforcing its position in domestic battery material commercialization. This news has sparked significant bullish momentum and speculation around its low float; however, a vocal segment of the community expresses skepticism, citing the company's history of frequent stock dilution and reverse splits. The broader conversation reflects ongoing interest in critical mineral recycling and securing US supply chains.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending due to news of its major shareholder, Berkshire Hathaway, filing a prospectus for a potential stake sale, which has triggered a significant share price decline. This has sparked a lively debate among investors, with many viewing the dip as an "overreaction" and a "buying opportunity" for a defensive stock with a substantial dividend, while others focus on long-term competitive challenges and the upcoming company split.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 9.2% Higher - Still a Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Up 9.2% - Here's Why...

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Up 22.1% in December

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) saw a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 49,429,420...

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 5.5% - Should You Sell?

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 5.5% - Should You Sell...

<ul class="summary-bullets"><li>The European study is expected to enroll 40 newly diagnosed AML patients.</li><li>Enrollment at U.S. sites is planned to begin in the first quarter of 2026, with European enrollment anticipated in the second quarter of 2026, the company said.</li><li>SLS stock is on track to end in the red in five of the last seven sessions.</li></ul>SELLAS Life Sciences Group Inc (SLS) stock was in the spotlight after it signed an agreement with IMPACT-AML (Acute Myeloid Leukemia) to expand the clinical development of SLS009, a targeted cancer therapy, into Europe.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has been trending down lately and is on track to end in the red in five of the last seven sessions. It was trading 3.2% lower. Last week, investors booked profits amid dilution concerns after Sellas reported $26.5 million in proceeds from the exercise of common stock warrants, in addition to its estimated cash and cash equivalents of $71.8 million as of December-end.<h2 class="st-heading-2">IMPACT-AML Tie Up</h2>The IMPACT-AML, a pan-European initiative within the EU Mission Cancer program, will conduct a European clinical study evaluating SLS009, providing SELLAS access to multiple clinical sites and a broader patient population. SELLAS aims to leverage the partnership to accelerate enrollment, expand patient access to SLS009, and maintain cost efficiency, it added.The European study is expected to enroll 40 newly diagnosed AML patients with high-risk features to evaluate SLS009 in combination with azacitidine and venetoclax, medications to treat cancer. Enrollment at U.S. sites is planned to begin in the first quarter of 2026, with European enrollment anticipated in the second quarter of 2026, the company said.<h2 class="st-heading-2">Retail Chatter</h2>Despite the intraday decline, retail sentiment on Stocktwits remained in the ‘bullish’ zone over the past 24 hours, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/SLS_jpg_8c87a5394f.webp" alt="SLS.jpg">One user saw the IMPACT-AML development as a positive for the stock and wondered why bears were still selling.<stembedurl>https://stocktwits.com/insidersruleloosersdrool/message/641795770</stembedurl>Another user said validating SLS009 in both the U.S. and the EU simultaneously makes the drug more attractive to a global buyer like Novartis.<stembedurl>https://stocktwits.com/Cresskill198/message/641779078</stembedurl>SLS shares have shot up 345% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-ibrx-stock-gain-retail-attention-today/cmULjP5R4eA">IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling. (Photo by Yuichiro Chino/Getty Images)

SLS Stock In Spotlight On EU Expansion For Cancer Therapy – Retail Says Potential Catalyst For Buyout

The IMPACT-AML program will conduct a European clinical study evaluating SLS009 and provide SELLAS access to multiple clinical sites and a broader patient population.

Equity

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 10.3% - Here's What Happened

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 10.3% Higher - Time to Buy...

<ul class="summary-bullets"><li>On Thursday, Sellas said that it received approximately $26.5 million in proceeds from the exercise of common stock warrants.</li><li>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.</li><li>The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) fell for the fourth straight session on Friday as investors resorted to profit taking amid dilution concerns.Shares of the company traded 13% lower at $3.34 at the time of writing, after <a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-breaches-5-dollar-level-after-over-3-years/cmxuTsiR4RS">breaching</a> the $5 threshold for the first time in over three years earlier this week.On Thursday, Sellas said that it received approximately $26.5 million in proceeds from the exercise of common stock warrants. This is in addition to the company’s estimated cash and cash equivalents of $71.8 million as of December-end.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SLS stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.A Stocktwits user expressed disappointment at the company diluting shares of the company by exercising warrants provided it has “sufficient cash” to carry out ongoing trials. However, they expect the price to be back up by February.<stembedurl>https://www.stocktwits.com/jackobull/message/641370638</stembedurl>Another, however, said that there is no “legitimate reason” to sell the stock. “...we longs know this is short lived. &nbsp;VERY short lived. &nbsp;It will explode upward from this oversold action,” they wrote.<stembedurl>https://www.stocktwits.com/Wut_About_Bob/message/641368167</stembedurl><h2 class="st-heading-2"> What Drove The Recent Rally?</h2>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy. AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding.The ongoing GPS trial is an overall survival study, and final analysis is expected once 80 deaths have occurred. As of December 26, 72 deaths have occurred, the company <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-group-stock-soars-as-it-nears-final-analysis-in-cancer-study/cL7dROARExt">said</a> last month, highlighting that it had previously expected 80 patient deaths to occur by December end.“While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results,” SELLAS CEO Angelos Stergiou said at the time. The announcement kickstarted a rally that mostly sustained through late December and early January.Last week, Maxim analyst Jason McCarthy noted that delays in an event-driven trial like SELLAS’ could be suggestive of extended survival benefit from GPS.Besides GPS, SELLAS has another experimental drug in its pipeline called SLS009 also being developed to target certain cancers.According to data from Koyfin, all three of the analysts covering SELLAS rate it ‘Buy’ or higher. The stock has an average price target of $6.83, hinting at significant potential upside.<a href="https://stocktwits.com/symbol/SLS">SLS shares</a> have nearly tripled over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/kalvista-pharmaceuticals-stock-rallies-after-hours-on-strong-genetic-disorder-drug-sales-kickstart/cmUbnxGR45Z">KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

SELLAS Life Sciences Falls For Fourth Straight Session — What’s Driving The Sell Off?

Shares of the company traded 13% lower at $3.34 at the time of writing.

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 8.4% - Here's Why

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 8.4% - Here's Why...

<ul class="summary-bullets"><li>Headlines from CES reignited enthusiasm around AI hardware and autonomous tech.</li><li>Despite the dip, retail sentiment on Stocktwits toward SPY and QQQ remained bullish.&nbsp;</li></ul>U.S. stock futures were trading in the red early Tuesday as investors balance AI optimism from CES, while awaiting crucial jobs data later this week.As of 3:50 a.m. ET on Tuesday, Nasdaq 100 futures and S&amp;P 500 futures fell 0.1%, and the Dow futures fell 0.2%, while Russell 2000 futures fell 0.4%.On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, has remained ‘bullish’, amid normal message volumes.Trending Stocks To Watch Nvidia (NVDA):&nbsp;At CES, Jensen Huang&nbsp;announced Nvidia’s next-generation AI chips, Vera Rubin, a successor to&nbsp;its Blackwell architecture, which would go on sale in the second half of the year. It is also joining the push to develop self-driving cars, reinforcing its position as a full-stack AI platform company, not just a chipmaker.&nbsp; Tesla (TSLA): CEO Elon Musk downplayed concerns around Nvidia’s newly unveiled Alpamayo autonomous driving AI.&nbsp; Advanced Micro Devices, Inc. (AMD)&nbsp;garnered retail attention on Stocktwits after the chipmaker&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-crashes-ces-2026-with-all-out-offensive-against-nvidia/cmxwVexR4Tb">launched</a> a slew of AI chips for computers, data centers, and gaming at the CES trade show in Las Vegas. Intel (INTC)&nbsp;unveiled its latest laptop processors, the Core Ultra Series 3, which are set to roll out in new computers later this month. Also, keep an eye on Chevron (CVX), Exxon Mobil Corp (XOM), amid political developments in Venezuela. OneStream (OS):&nbsp;HG Capital is reportedly nearing a deal to acquire the financial software firm.&nbsp; Sellas Lifesciences (SLS)&nbsp;is the top trending ticker on Stocktwits at the time of writing.&nbsp; Aeva (AEVA)&nbsp;is on the retail radar after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tiny-lidar-player-aeva-stock-rockets-over-25-after-hours-on-nvidia-deal/cmxwXUUR4RV">announcing</a> its 4D LiDAR will be integrated into the Nvidia Drive Hyperion platform. PLTR (Palantir) and&nbsp;RCAT (Red Cat Holdings) are trending. Traders are&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/red-cat-roars-back-venezuela-speculation-sends-drone-stock-flying/cmxw13MR4Rs">speculating</a> on increased contract awards for surveillance and drone technology.&nbsp; Zeta Global (ZETA)&nbsp;is gaining traction following the collaboration with OpenAI to enhance its marketing platform. And&nbsp;Alumis (ALMS) is scheduled to report topline Phase 3 data for envudeucitinib in plaque psoriasis before the open, with a conference call at 8:00 a.m. ET.&nbsp; Other noteworthy tickers trending on Stocktwits at the time of writing were Amazon (AMZN), Momentus In (MNTS), Bank of America (BAC), Alibaba (BABA), Paramount Skydance (PSKY), and Apteva Therapeutics (APVO) Other Catalysts To Watch With no significant economic releases due Tuesday, traders are expected to continue tracking CES developments and positioning ahead of key jobs data later this week. Siemens is expected to showcase its Industrial Metaverse, while Lenovo CEO is expected to unveil the “AI for All” strategy today. For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Edge Lower Despite CES-Driven AI Optimism: Why NVDA, TSLA, AMD, AEVA, OS Are On Traders' Radar Today

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data.

Markets seem to be balancing CES-driven AI optimism with caution ahead of upcoming jobs data this week.


<ul class="summary-bullets"><li>SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia.</li><li>The stock has had a good run since the company said that slower deaths in the GPS trial might imply further clinical benefit.</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) garnered retail attention on Monday after it breached the $5 threshold after over three years during the day trading session.The stock closed 15% higher in the regular trading session to close at $5 and traded 2% higher after hours.<h2 class="st-heading-2">Retail Speaks</h2>On Stocktwits, retail sentiment around SLS stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘extremely low’ to ‘low’ levels.A bullish Stocktwits user rejoiced at the new levels.<stembedurl>https://www.stocktwits.com/Duncan74/message/640892449</stembedurl>Another expressed optimism for a buyout of the company for as much as $25 billion.<stembedurl>https://www.stocktwits.com/Mjohns92/message/640889738</stembedurl><h2 class="st-heading-2">What’s Driving The Rally?</h2>SELLAS is currently <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-group-stock-soars-as-it-nears-final-analysis-in-cancer-study/cL7dROARExt">evaluating</a> Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy. AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding.The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. As of December 26, 72 deaths have occurred, the company said last month, highlighting that it had previously expected 80 patient deaths to occur by December end.“While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results,” SELLAS CEO Angelos Stergiou then said.Last week, Maxim analyst Jason McCarthy noted that delays in an event-driven trial like SELLAS’ could be suggestive of extended survival benefit from GPS.Besides GPS, SELLAS has another experimental drug in its pipeline called SLS009 also being developed to target certain cancers.According to data from Koyfin, all three of the analysts covering SELLAS rate it ‘Buy’ or higher. The stock has an average price target of $6.83, hinting at further potential upside.<a href="https://stocktwits.com/symbol/SLS">SLS shares</a> have nearly tripled this year and multiplied by about five times in value over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/crnx-stock-gains-nbix-shares-drop-on-positive-results-from-genetics-disorder-trial/cmxMxA1R4Rf">CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

SLS Stock Breaches $5 Level After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B 

SELLAS Life Sciences closed 15% higher in the regular trading session to close at $5 and traded 1% higher after hours.

SLS Stock Breaches $5 Levels After Over 3 Years: Retail Now Eyes Buyout For As Much As $25B 

SELLAS Life Sciences closed 15% higher in the regular trading session to close at $5 and traded 1% higher after hours.


SELLAS Life Sciences Group (NASDAQ:SLS) Sets New 52-Week High - Should You Buy?

SELLAS Life Sciences Group (NASDAQ:SLS) Reaches New 12-Month High - Should You Buy...

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Stocktwits

Stocktwits Polls

Traders are actively speculating on a multi-billion dollar acquisition, with many anticipating a $40B+ valuation from major pharmaceutical companies due to compelling trial data.

High short interest and growing bullish sentiment point to a potential short squeeze, with calls for 'bears' to cover before key catalysts hit.

The community is eagerly anticipating final Phase 3 trial results for GPS and the IDMC meeting, expecting positive data to confirm the drug's efficacy for AML.

Excitement is building for the upcoming 'first patient dosed' announcement for SLS009, positioning it as a significant second catalyst and value driver.

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc